NASDAQ · Biotechnology · USD
XORTX Therapeutics Inc. (XRTX) Stock Analysis
XORTX Therapeutics Inc. (XRTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
XRTX Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.97
- Previous Close
- $0.96
- Day's Range
- 0.90–1.05
- 52-Week Range
- 0.90–3.89
- Volume
- 72.29K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.58
Valuation
- Market Cap
- $1.69M
- P/E Ratio
- unprofitable
- Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
- 1.16
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −2.61
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$2.66M
- Shares Outstanding
- 1.82M
- 1-Year Return
- −74.34%
Dividend and dates
- Earnings Date
- November 12, 2026estimated
- Avg Volume
- 720.24K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, XRTX closed at $0.93, −74.34% over 1 year.
XORTX Therapeutics Inc. (XRTX) has a market capitalization of $1.69M.
In fiscal 2025, XRTX reported revenue of $0.00.
XRTX Stock Return by Calendar Year
XORTX Therapeutics Inc. (XRTX) return since Sep 2021: what $10,000 became
- 1 year
- $10,000 $2,566
- −74.34%
- 5 years
- $10,000 $8
- −99.92%
- Since Sep 2021
- $10,000 $5
- −99.95%
If you had invested $10,000 in XORTX Therapeutics Inc. (XRTX) at the close on September 23, 2021, the earliest close on record here, it would have been worth $5 at the close on October 21, 2026: −99.95% in total, −78.01% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −66.90% |
| 2025 | −50.27% |
| 2024 | −51.08% |
| 2023 | −96.47% |
| 2022 | −60.59% |
| 2021 (partial year) | −59.11% |
As of October 21, 2026.
XRTX Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$2.66M | — |
| 2024 | $0.00 | −$3.31M | — |
| 2023 | $0.00 | −$2.16M | — |
| 2022 | $0.00 | −$7.72M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$3.26M | −$2.66M | — |
| 2024 | $0.00 | — | −$4.12M | −$3.31M | — |
| 2023 | $0.00 | — | −$6.05M | −$2.16M | — |
| 2022 | $0.00 | — | −$10.29M | −$7.72M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
XORTX Therapeutics (XRTX) Stock Jumps Over 22% After Hours: Here's Why
BenzingaXORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
YahooXORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
YahooXORTX Outlines Anticipated FDA IND Submission For XRx-026 Gout Program
BenzingaXORTX Therapeutics (XRTX) Stock Climbs 16% After Hours: Here's What You Need to Know
BenzingaXORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
Yahoo
All 9 articles ↓Show fewer ↑
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B






